Gene Biotherapeutics (CRXM) 10-Q 3 Sep 21 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Aug. 28, 2021
Cover [Abstract]
Entity Registrant Name	Gene Biotherapeutics, Inc.
Entity Central Index Key	0000772320
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		64,931,888
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,926	$ 400
Prepaid expenses and other assets	111,988	32,395
Total current assets	114,914	32,795
Property and equipment, net	2,219	2,640
Other long term	12,541
Total assets	129,674	35,435
Current liabilities:
Accounts payable	1,040,045	967,126
Accrued liabilities	2,890,440	2,796,689
Note Payable	281,976	273,749
Advances from officer	690,050	725,425
Total current liabilities	4,902,511	4,762,989
Notes payable-long term	245,740	122,209
Total liabilities	5,148,251	4,885,198
Commitments and contingencies
Stockholders' deficit:
Common stock issuable	600,000	600,000
Series A Convertible Preferred stock, $0.0001 par value; 40,000,000 shares authorized; issued and outstanding 790 March 31, 2020 and 790 at December 31, 2019
Common stock, $0.0001 par value; 200,000,000 shares authorized; issued and outstanding 14,489,399 at March 31, 2020 and 14,489,399 at December 31, 2019, respectively	1,449	1,449
Additional paid-in capital	114,020,581	114,020,581
Accumulated deficit	(119,062,053)	(118,912,290)
Total controlling interest	(4,440,023)	(4,290,260)
Non-controlling interest	(578,554)	(559,503)
Total stockholders' deficit	(5,018,577)	(4,849,763)
Total liabilities and stockholders' deficit	$ 129,674	$ 35,435

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	14,489,399	14,489,399
Common stock, shares outstanding	14,489,399	14,489,399
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	790	790
Preferred stock, shares outstanding	790	790

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses
Research and development	$ 46,605	$ 63,379
Selling, general and administrative	106,278	179,599
Total operating expenses	152,883	242,978
Loss from operations	(152,883)	(242,978)
Other expenses:
Interest expense	(15,931)	(10,129)
Net loss	(168,814)	(253,107)
Net loss attributable to the non-controlling interest	(19,051)	(26,736)
Net loss attributable to the controlling interest	$ (149,763)	$ (226,369)
Net loss attributable to controlling interest per share:
Basic and diluted	$ (.01)	$ (.02)
Weighted average common shares outstanding	14,489,399	14,473,967

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows from Operating Activities
Net (Income) loss	$ (168,814)	$ (253,107)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	421	15,942
Deferred rent amortization		(2,722)
Changes in operating assets and liabilities
Prepaid expenses and other assets	(79,594)	5,305
Deposits and other long-term assets	(12,541)
Accounts payable	72,920	8,863
Accrued liabilities	93,751	185,375
Net cash used in operating activities	(93,857)	(40,344)
Cash Flows from Financing Activities
Proceeds (Payments) from officer's loan	(35,375)	(45,503)
Increase in notes payable	131,758	8,137
Net cash provided by financing activities	96,383	(37,366)
Net increase (decrease) in cash	2,526	(77,710)
Cash and cash equivalents at beginning of period	400	82,115
Cash and cash equivalents at end of period	2,926	4,405
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$ 4,173	$ 1,991

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Stockholders (Deficit)/Equity - 3 months ended Mar. 31, 2020 - USD ($)	Common Stock [Member]	Series A Convertible Preferred Stock [Member]	Common Stock Issuable [Member]	Additional Paid-In Capital [Member]	Controlling Interest Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 1,449		$ 600,000	$ 114,020,581	$ (118,912,290)	$ (559,503)	$ (4,849,763)
Balance, shares at Dec. 31, 2019	14,489,399	790
Issuance of common stock on conversion of preferred stock	$ 0			0
Non-controlling interest						(19,051)	(19,051)
Net income					(149,763)		(149,763)
Balance at Mar. 31, 2020	$ 1,449		$ 600,000	$ 114,020,581	$ (119,062,053)	$ (578,554)	$ (5,018,577)
Balance, shares at Mar. 31, 2020	14,489,399	790

Organization and Liquidity

Organization and Liquidity	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Liquidity	Note 1. Organization and Liquidity Organization Gene Biotherapeutics Inc. (the “Company”) was initially incorporated in Delaware in December 2003. The Company is a late-stage biotechnology company focused on the clinical and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets, primarily for the treatment of cardiovascular disease. The technology platform is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. The Company’s current business is focused exclusively on the development of Generx, an angiogenic gene therapy product candidate, initially targeted for patients with refractory angina due to advanced coronary artery disease and other forms of ischemic heart disease including congestive heart failure, through our 85% owned subsidiary Angionetics Inc. The Company does not currently have any other products or other product candidates and has not generated any revenues from operations for the three-month period ended March 31, 2020. In May 2020, after the period covered by this report, we entered into a Preferred Stock Purchase Agreement with Nostrum Pharmaceuticals, LLC (“Nostrum”), selling Nostrum 1,700,000 shares of our newly authorized Series B Convertible Preferred Stock in exchange for $1.7 million. In addition, to further support the operations of the Company for the period May 2021 through July 2021, subsequent to this reporting period, Nostrum invested an additional $292,000, into the Company. Nostrum is the parent company of Nostrum Laboratories, Inc., a privately held pharmaceutical company engaged in the formulation, commercialization, marketing and sale of specialty pharmaceutical products and controlled release, orally administered, branded and generic drug products. We have used the proceeds from the sale of the Series B Convertible Preferred Stock to fund working capital requirements in preparation for conducting the U.S. FDA-approved Phase 3 clinical trial for our Generx product candidate. We believe that Nostrum’s assets and experience in the formulation and commercialization of pharmaceutical products will facilitate the administration and completion of the Phase 3 clinical trial for Generx on a cost-effective basis. Refer to the Subsequent Section for further discussion. Liquidity and Going Concern As of March 31, 2020, the Company had $2,926 in cash and cash equivalents. The Company’s working capital deficit as of March 31, 2020 was $4,787,597 and the Company has incurred recurring losses and has an accumulated deficit of $119,062,053. During the three-month period ended March 31, 2020, the Company used approximately $93,857 of cash in our operating activities. The Company also began restructuring efforts with its vendors in 2019, resulting in the forgiveness of approximately $1.66 million in vendor payables and additional forgiveness of approximately $68,000 in the quarter ending June 30, 2020. On April 10, 2020, after the period covered by this report, we transferred our residual rights in Excellagen to Shanxi Taxus Pharmaceuticals Co. Ltd. in exchange for the release of any rights or claims in ownership interest in Gene Biotherapeutics. As a result, we no longer have an interest in Excellagen, other than the right to receive royalty payments from Olaregen totaling up to $3,350,000, based on monthly net sales of Excellagen worldwide, excluding Greater China, the Russian Federation, and countries in the Commonwealth of Independent States. In connection with this transaction, Shanxi agreed to apply previously funded $600,000 subscription payment in exchange for the rights to Excellagen in the Greater China, the Russian Federation and countries in the Commonwealth of Independent States, and Shanxi released any future rights or claims against us. On April 10, 2020, after the period covered by this report, our Angionetics, Inc. subsidiary entered into a Distribution and License Agreement with Shanxi (as amended, the “Shanxi License Agreement”), granting Shanxi certain license rights with respect to our Generx product candidate. The distribution and license rights commence only after we obtain U.S. FDA approval for marketing and sale of Generx in the United States. The license rights include (a) a non-exclusive right to manufacture Generx products in China, and (b) an exclusive right to market and sell Generx products in Singapore, Macau, Hong Kong, Taiwan, any other municipality other than mainland China where Chinese (Mandarin or Cantonese) is the common language, the Russian Federation, and the Commonwealth of Independent States (i.e., Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan). The Shanxi License Agreement provides for a royalty ranging from 5% up to 10% based on the level of annual net sales of the Generx product sold by Shanxi in the licensed territory. Refer to the Subsequent Events section for a further discussion on this matter. The Company anticipates that negative cash flows from operations will continue for the foreseeable future. We have yet to generate positive cash flows from operations and we are essentially dependent on external funding sources to support the Company’s research, development and commercialization activities. The Company’s history of recurring losses and uncertainties as to whether operations will become profitable raises substantial doubt about its ability to continue as a going concern for the next twelve months from the date of issuance of these financial statements. We do not have any unused credit facilities. We intend to pursue sources of working capital from non-dilutive funding channels to support the Company’s operations that could include, but not be limited to, (1) up to $3.350 million from potential royalties from commercial sales of Excellagen® from certain geographic regions, including the United States; (2) Federal government sponsored research grants; (3) agreements and arrangements covering distributor and strategic partnerships and drug royalty agreements based on the commercial sale of Generx following the successful completion of the planned FDA-cleared, Phase 3 AFFIRM clinical study and FDA registration in the U.S., and additional registrations to market and sell Generx in other countries internationally. At the appropriate time, with favorable market conditions, and an appropriate enterprise value reflective of the Company’s clinical status and the Generx [Ad5FGF-4] economic potential, we could also consider the sale of equity and debt securities in a privately negotiated structured transactions or public capital market offerings. The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates our continuation as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue operations is dependent on the execution of management’s plans, which include the raising of additional capital through the equity and/or debt markets, until such time that funds provided by operations are sufficient to fund working capital requirements. Without additional capital the Company will not have sufficient resources for research, product development and sales and marketing efforts to bring Generx to commercialization. The consolidated financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Impact of Coronavirus Outbreak On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The Company did not experience substantial effects from the COVID- 19 outbreak on its operations for the period ended March 31, 2020. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity on its future operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2—Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”). Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, accounts receivable, inventories, accounts payable, and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Use of Estimates and assumptions and critical accounting estimates and assumptions. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary. Principles of Consolidation The consolidated financial statements include the accounts of Gene Biotherapeutics Inc., and its consolidated subsidiaries, Angionetics Inc., Activation Therapeutics, Inc. and LifeAgain Insurance Solutions, Inc. All significant inter-company transactions and balances have been eliminated in consolidation. The profit and losses of Angionetics are allocated among the controlling interest and the non-controlling interest in the same proportions as their ownership interests. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Concentration of Credit Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist of cash and cash equivalents. At times, our cash and cash equivalents may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. As of March 31, 2020, the Company had no cash and cash equivalent balances in excess of the federally insured limit of $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Property and Equipment, net Property and equipment are stated at cost and include equipment, installation costs and materials less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of the assets range from 3 to 5 years. Leasehold improvements are amortized over the lesser of the useful lives or the term of the respective lease. Expenditures for maintenance and repairs, which do not extend the useful life of the assets, are charged to expense as incurred. Gains or losses on disposal of property and equipment are reflected in general and administrative expenses in the statement of operations. Impairment of Long-Lived Assets The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assts are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized no impairment losses during any of the periods presented in these financial statements. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity. Revenue Recognition The Company’s products have not reached commercialization, accordingly revenue from product sales have not been recognized. For arrangements that include sales-based royalties, the Company recognizes revenue based on an assessment of the probability of achievement. There is considerable judgement involved in determining whether it is probable that royalties will be collected. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. To date, the Company has not recognized revenue from product sales or for royalties. Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for research and development employees. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income(loss) in the years in which those temporary differences are expected to be recovered or settled. Due to the Company’s history of losses, a full valuation allowance was recognized against the deferred tax assets as of December 31,2020. The Company expects that it will continue to experience operating losses. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the three-month period ended March 31, 2020, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes in unrecognized tax benefits within the next twelve months. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes our tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits. Under the provision of ASC 740-10, the Company recognizes the impact of a tax position in its financial statements if the position is more likely than not to be sustained upon examination based on the technical merits of the position. For the year period ended March 31, 2020, the Company had no material unrecognized tax benefits, and based on the information currently available, no significant changes in unrecognized tax benefits are expected in the next twelve months As of the tax year ending December 31,2019 the Company has net operating loss carryforwards for federal income tax purposes of approximately $91.4 million and net operating loss carryforwards for state income tax purposes of approximately $52.5 million. The net operating losses begin to expire in 2023 for federal income purposes and in 2028 for state income tax purposes. The federal net operating loss carryover includes $258,000 of net operating losses generated in 2018 and later. Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income. The Company also has R&D tax credits available for federal and state purposes of $1.8 million and $1.9 million, respectively. The federal R&D credits will begin to expire December 31, 2035. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those net operating losses are available. The Company considers projected future taxable income and tax planning strategies in making their assessment. At present, the Company does not have a sufficient history of income to conclude that it is more-likely-than-not that the Company will be able to realize all of our tax benefits in the near future and therefore the Company has established a valuation allowance for the full value of the deferred tax asset. In December 2017, the Tax Cuts and Jobs Act (the “2017 Act) was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 34 percent to 21 percent for tax years beginning after December 31, 2017. In 2017, the Company recorded provisional amounts for certain enactment-date effects of the act by applying the guidance in Staff Accounting Bulletin No. 118 (“SAB 118”). In 2018 and 2017, the Company recorded $0 net tax expense related to the enactment-date effects of the Act related to the remeasurement of deferred tax assets and liabilities. As of December 31, 2018, the Company completed its accounting for all of the enactment-date income tax effects of the Act and no adjustments were made to the provisional amounts recorded on December 31, 2017. As of December 31, 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they were expected to reverse in the future (which was generally 21%), by recording a provisional amount of $14.5 million, which was fully offset by valuation allowance. Upon further analysis of certain aspects of the Act and refinement of our calculations during the 12 months ended December 31, 2018, the Company determined that no adjustment was necessary to our provisional amount. Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC Section 382 and 383, the Company’s ability to use net operating loss and R&D tax credit carryforwards (“tax attribute carries forwards”) to offset future taxable income is limited if we experience a cumulative change in ownership of more than 50% within a three-year testing period. The Company had an ownership change on May 22, 2020 as result of the Nostrum investment. Accordingly for periods subsequent to May 22, 2020, the annual utilization of the net operating losses that are carried forward are expected to be limited. Further, the Company’s deferred tax assets associated with such tax attributes are expected to be significantly reduced upon realization of the ownership change within the meaning of IRC 382. The Company incurred an operating loss for the period ended March 31, 2020 and expects to have operating losses and federal and state tax losses for the full year December 31, 2020. Common Stock Purchase Warrants The Company accounts for the issuance of common stock purchase warrants issued in connection with capital financing transactions. The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside of our control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss attributable to the controlling interest per common share for the three-month period ended March 31, 2020, because their effect would be anti-dilutive. As of March 31, 2020, there were potentially dilutive securities issued and outstanding which consisted of Series A Convertible Preferred Stock, that were convertible into 4,388,889 share of Common Stock, and there were stock options and warrants to acquire up to 14,811,333 shares of the Company’s Common Stock. Stock-Based Compensation The Company recognizes the fair value of all share-based payment awards in the Statement of Operations over the requisite vesting period for each expected volatility, expected term, and risk-free interest rate. The Company estimated the fair value of an option award on the date of grant using the Black–Scholes option valuation model. The Black–Scholes option valuation model requires the development of assumptions that are input into the model. These assumptions are the expected stock volatility, the risk–free interest rate, the option’s expected life, the dividend yield on the underlying stock and the expected forfeiture rate. Expected volatility is calculated based on the historical volatility of our common stock over the expected option life and other appropriate factors. Risk–free interest rates are calculated based on continuously compounded risk–free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its common stock and does not intend to pay dividends on its common stock in the foreseeable future. The expected forfeiture rate is estimated based on historical experience. Determining the appropriate fair value model and calculating the fair value of equity–based payment awards require the input of the subjective assumptions described above. The assumptions used in calculating the fair value of equity–based payment awards represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and the Company uses different assumptions, equity–based compensation could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If the actual forfeiture rate is materially different from the estimates, the equity–based compensation could be significantly different from what the Company has recorded in the current period. Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3—Property and Equipment Property and equipment consisted of the following: March 31, December 31, 2020 2019 Computer and telecommunication equipment $ 12,902 $ 12,902 Office equipment 5,871 5,871 Office furniture and equipment 7,396 7,396 Leasehold improvements 177,436 177,436 203,605 203,605 Accumulated depreciation and amortization (201,386 ) (200,965 ) Property and equipment, net $ 2,219 $ 2,640 Depreciation and amortization of property and equipment totaled $421.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	Note 4—Accrued Liabilities Accrued Liabilities consisted of the following: March 31, December 31, 2020 2019 Payroll and benefits $ 2,761,467 $ 2,657,717 Other 128,973 138,973 Total $ 2,890,440 $ 2,796,690

Advances from Related Party-Off

Advances from Related Party-Officer	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Advances from Related Party-Officer	Note 5—Advances from Related Party-Officer As of March 31, 2020, and December 31, 2019, $690,050 and $725,425 respectively, was owed to the Company’s Chief Executive Officer for cash advances made to the Company to fund working capital requirements incurred in the ordinary course of business. These advances are non-interest bearing with no fixed terms of repayment. During the period ended March 31, 2020, the Company repaid $35,375. Subsequent to the reporting period, effective in June, 2020, the Company is repaying the loan in equal monthly installments of $20,000.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6—Commitments and Contingencies Lease Commitments In June 2016, the Company entered into a thirty-eight-month lease agreement to lease office space commencing on September 30, 2016. The approximate base monthly rent in the first, second and third years is $3,500, $3,700, and $3,800, respectively. The base monthly rent in the final two months of the agreement is $3,900. The total base rent over the lease term equals $139,800. The lease was extended until July 31, 2020, on a month-to-month basis. On July 8, 2020, the Company entered into a twenty-nine-month lease for approximately 3,039 square feet of office space in San Diego, California commencing on August 1, 2020. The monthly base rent is $6,685 and increases by three percent (3%) on each anniversary of the Commencement Date. Contingent Liability During the year ended December 31, 2019, the Company entered into various restructuring efforts including the restructuring of certain payables with its vendors to pay certain amounts due contingent on the receipt of FDA approval on Generx or contingent on the FDA approval and commercial sales of Generx. Since it is not determinable when and if Generx will receive FDA approval and the Company will achieve commercial sales, the Company has reflected these re-negotiated amounts due as contingent liabilities where it is not determinable when and if the amounts will ultimately be paid. The total liabilities payable by the Company in the event of FDA approval is $172,449 and an additional amount totaling $225,000 is payable when commercial sales cumulatively reach $100 million for Generx. Since the Company does not know if FDA approval will be received for the Generx product, it is not determinable if and when this payment will be made by the Company. Accordingly, these amounts have been reported as a contingent liability and have not been included in accounts payable and accrued liabilities. Deferred Compensation As of March 31, 2020, we had an outstanding balance in accrued but unpaid salaries and benefits for current and former employees totaling $2,926,717. In January 2020, all affected current and former employees agreed to defer their compensation, less applicable tax withholdings, upon the earliest to occur of (a) the FDA’s approval of Generx for marketing and sale in the U.S.; (b) the EMA approval of Generx for marketing and sale in the European Union and the United Kingdom; (c) the sale of Generx to an independent third party for an aggregate value equal to or greater than $35,000,000; (d) our entry into a strategic partnership that would facilitate a capital contribution equal to or greater than $35,000,000 for the purpose of supporting the clinical and commercial development of Generx; (e) our successful completion of a public or private equity offering for the issuance of its common stock equal to $35,000,000; or (f) at such other time, as our board of directors determines that we have the financial ability to make such payments without jeopardizing our ability to operate as a going concern. License Fees Technology License Agreements As of October 2019, the outstanding and unpaid amount due and payable under the UC License Agreement totaled $1,006,709. As part of the Company’s restructuring efforts, the Company and the University of California reached a settlement agreement in the amount of $172,449, payable as $100,000 in quarterly cash payments of $8,333 over a 36 month-month period, with the first payment commencing on June 15, 2020, and an additional lump sum payment of $72,449 payable upon FDA approval of Generx. As of November 2019, the Company and the New York University reached an agreement to settle total amounts due under this agreement for $400,000 payable as follows: (1) $75,000 in six quarterly payments of $12,500 commencing June 15, 2020, with additional contingent payments due as follows (2) $100,000 payable upon FDA approval to market and sell Generx; and (3) an additional amount totaling $225,000 when commercial sales cumulatively reach $100 million for Generx. The Company has not reflected the contingent amounts payable of $397,449 in the Consolidated Balance Sheet as the payable is contingent on FDA approval and commercialization of the product. Since it is not determinable when and if FDA approval will be received, it is not determinable if and when this payment will be made by the Company. Accordingly, these amounts have been reported as a contingent liability. As a result of these settlements, the agreements are deemed terminated and no further amounts and royalties are payable by the Company. Legal Proceedings In the course of our business, the Company is routinely involved in proceedings such as disputes involving goods or services provided by various third parties, which the Company does not consider likely to be material to the technology we develop or license, or the products we develop for commercialization, but which can result in costs and diversions of resources to pursue and resolve.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	Note 7—Stockholders’ Equity Common Stock In April 2015, the Company entered into a term sheet with Shenzhen Qianhai Taxus Capital Management Co., Ltd. (“Shenzhen Qianhai Taxus”), a company affiliated with Shanxi Taxus Pharmaceuticals Co. Ltd., whereby the Company proposed to sell Shenzhen Qianhai Taxus 600,000 shares of common stock in our Angionetics subsidiary in exchange for $3.0 million in cash. The $3.0 million was to be paid in tranches that were to be completed by May 31, 2015. Shenzhen Qianhai Taxus paid $600,000 of the financing, which was recorded as common stock issuable. Shenzhen Qianhai Taxus did not complete this transaction. This subscription was committed and not refundable to Shenzhen Qianhai Taxus. Shenzhen Qianhai Taxus was eligible to apply this amount toward the purchase of common stock of the Company or its subsidiaries based on terms and conditions approved by the Company’s Board of Directors. In April 2020, in connection with the Change of Control and restructuring efforts executed pursuant to the Preferred Stock Purchase Agreement, the Company entered into a Reaffirmation and Ratification Agreement with Shenzhen Qianhai Taxus (the “ Ratification Agreement Shenzhen Qianhai Taxus previously held approximately 24% of the Company shares as of March 31, 2020 and the chairman of Shenzhen Qianhai Taxus was also on the Board of Directors and Chairman of the Board of the Company. Following completion of the transaction with Nostrum, which included the issuance of the Series B Convertible Preferred Stock, the Chairman resigned from the Company’s Board of Directors. After the Nostrum Series B Preferred stock investment and excluding Nostrum’s Series A Preferred Stock investment and pending Series B Preferred issuances Shenzhen Qianhai Taxus and Nostrum own 1.6% and 70% of the voting common stock respectively as of August 28,2021. Preferred Stock Series A Preferred Stock Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. In April 2013, the Company entered into a securities purchase agreement with Sabby Healthcare Volatility Master Fund, Ltd. (“Sabby”) to purchase up to 4,012 shares of our newly authorized Series A Convertible Preferred Stock (the “Preferred Stock”) for maximum proceeds of $4.0 million. The Preferred Stock was convertible into shares of our common stock at an initial conversion price of $0.6437 per share. The conversion price is subject to downward adjustment if the Company issues common stock or common stock equivalents at a price less than the then effective conversion price. Sabby is limited to hold no more than 10% of Gene Biotherapeutics’ issued and outstanding common stock at any time. As long as the Preferred Stock is outstanding, the Company has also agreed not to incur specified indebtedness without the consent of the holders of the Preferred Stock. These factors may restrict our ability to raise capital through equity or debt offerings in the future. In July 2015, the Company entered into an Exchange and Redemption Agreement with Sabby relating to the 1,176 shares of Preferred Stock that remained outstanding at that time. Under the terms of the Exchange and Redemption Agreement, the Company agreed to reduce the conversion price of the Preferred Stock to $0.30 per share. The Agreement grants Gene Biotherapeutics (1) a right to redeem any or all of the outstanding Preferred Stock for its stated value (approximately $1,000 per share) at any time during a 120-day period after the date of the Agreement, and (2) increases the limitation on certain indebtedness contained in the Certificate of Designation for the Preferred Stock to allow Gene Biotherapeutics to borrow up to $250,000. The Company entered into the Agreement to increase our options for retiring the outstanding Preferred Stock and financing our continued business operations. As a result of the effective conversion price changing from $0.64 to $0.30 per share, the 1,176 shares of Preferred Stock outstanding at that time were convertible to 3,918,667 shares of Gene Biotherapeutics common stock, an additional 2,092,350 shares compared to before the conversion price change. As of March 31, 2020, and December 31, 2019, there were 790 Preferred Stock outstanding. Refer to the Subsequent Events section for further discussion on the Series A Preferred Stock. Series A Preferred Stock Purchase Agreement Between Nostrum and Sabby In May 2020, subsequent to this reporting period, concurrent with the sale of the Series B Preferred Stock, Nostrum acquired 220 shares of the Company’s Series A Preferred Stock from Sabby Master Healthcare Ltd. and agreed to purchase the remaining 570 shares of Series A Convertible Preferred Stock that are outstanding and held by Sabby. As a result of the issuance of the Series B Convertible Preferred Stock, each share of our Series A Convertible Preferred Stock became convertible into 88,496 shares of our Common Stock which totaled 50,442,489 shares of Common Stock. The Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock restricts Nostrum from converting any Series A Preferred Stock if Nostrum would beneficially own a number of shares of Common Stock in excess of 9.99% of the shares of Common Stock then issued and outstanding. As a result of its ownership of the Series B Convertible Preferred Stock, Nostrum is currently limited in its entirety from converting any shares of Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has no voting rights on general corporate matters, provided that the Series A Convertible Preferred Stock contain customary protective provisions. As of April 28, 2021, Sabby converted all of its remaining 570 shares of Series A Convertible Preferred Stock into 50,442,489 shares of Common and no further shares of the Series A Convertible Preferred Stock were purchased by Nostrum. As a result, Nostrum did not acquire any further shares of the Series A Convertible Preferred beyond their initial 220 share acquisition. Series B Convertible Preferred Stock Purchase Agreement with Nostrum In May 2020, subsequent to this reporting period we entered into a Preferred Stock Purchase Agreement with Nostrum Pharmaceuticals, LLC (“Nostrum”), selling Nostrum 1,700,000 shares of our newly authorized Series B Convertible Preferred Stock in exchange for $1.7 million, that are convertible into 150,442,478 shares of the Company’s Common Stock. Set forth below are the specific details of the terms and conditions of the Series B Convertible Preferred Stock. Amendment to Certificate of Incorporation and Amendment to Bylaws Covering the Series B Convertible Preferred Stock On May 21, 2020, the Company amended their Certificate of Incorporation with the filing of a Certificate of Designation to establish the rights, privileges, and preferences of a new class of our preferred stock designated Series B Convertible Preferred Stock (“Series B Preferred Stock”). The Series B Preferred has the following material terms and provisions: Dividends Voting Rights Conversion Liquidation In May 2020, the Board amended the Company’s bylaws to eliminate the classified Board. Directors will serve one-year terms until the next annual meeting of stockholders or until their successors are duly elected and qualified. Stock Options and Other Equity Compensation Plans The Company had an equity incentive plan that was established in 2005 under which 283,058 shares of our common stock was reserved for issuance to employees, non-employee directors and consultants. The 2005 Equity Incentive Plan expired on October 20, 2015, ten years after its adoption, and the Company is no longer able to issue share or awards under that plan. All options or other awards issued under the 2005 Equity Incentive plan prior to its expiration remain outstanding in accordance with their terms. At March 31,2020, there are no shares outstanding and available for future issuance under the option plan. There were no stock options, warrant under the Equity Incentive plan and no warrant issued outside of the plan to employees and consultants during the three-month period ended March 31, 2020. The total number of options and warrants outstanding and exercisable were 14,811,333 as of March 31, 2020 with a weighted average exercise price of $0.62 per share, and a weighted average remaining life of 4.42. Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Balance outstanding, January 1, 2017 12,116,334 $ 0.62 7.67 Granted — — — Exercised — — — Cancelled (unvested) — — — Expired (vested) (5,001 ) 0.62 — Balance outstanding, December 31, 2017 12,111,333 0.62 6.67 Granted — — — Exercised — — — Cancelled (unvested) — — — Expired (vested) — — — Balance outstanding, December 31, 2018 12,111,333 $ 0.62 5.67 Granted — — — Exercised — — — Cancelled (unvested) — — — Expired (vested) — — — Balance outstanding, December 31, 2019 12,111,333 $ 0.62 4.67 Balance exercisable, December 31, 2019 12,111,333 $ 0.62 4.67 Balance exercisable, March 31, 2020 12,111,333 $ 0.62 4.42 The Company calculates the fair value of stock options using the Black-Scholes option-pricing model. In determining the expected term, the Company separate groups of employees that have historically exhibited similar behavior with regard to option exercises and post-vesting cancellations. The option-pricing model requires the input of subjective assumptions, such as those included in the table above. The volatility rates are based principally on our historical stock prices and expectations of the future volatility of its common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The total expense to be recorded in future periods will depend on several variables, including the number of share-based awards and expected vesting. As of March 31, 2020, there was a $0, intrinsic value to the outstanding and exercisable options and warrants, respectively. Warrants In October 2017, the Company issued 1,000,000 fully vested Common Stock warrants to Landmark, in exchange for economic monetization and business mobilization services for the Company. The warrants are exercisable at any time from October 9, 2017 (initial exercise date) and on or prior to the close of business on the 10-year anniversary from the initial exercise date, October 8, 2027, at an exercise price of $0.25 per share. The warrants had a fair value of $0.15 per share and the Company has recognized $150,000 as consulting costs in the statement of operations during the fourth quarter ended December 31, 2017. In November 2017, the Company issued 700,000 fully vested Common Stock warrants to a consultant for ongoing scientific and business consulting services. The warrants are exercisable at any time from November 14, 2017 (the grant date) for a period up to 10 years at an exercise price of $0.25 per share. The warrants had a fair value of $0.11 per share, determined using the Black-Scholes valuation model, and the Company has recognized $79,222 as consulting costs in the statement of operations during the further quarter ended December 31, 2017. In April 2018, the Company issued an additional 1,000,000 fully vested Common Stock warrants to Landmark as final consideration paid upon completion of the 6-month Agreement. The Common Stock warrants are exercisable at any time from April 23, 2018 (initial exercise date) and on or prior to the close of business on the 10-year anniversary from the initial exercise date, April 22, 2028, at an exercise price of $0.25 per share. The warrants had a fair value of $0.08 per share, determined using the Black-Scholes valuation model. The Company recognized approximately $80,000, representing the aggregate fair value of the warrants as consulting expenses in the statement of operations during the second quarter ended June 30, 2018. The Company calculates the fair value of stock options using the Black-Scholes option-pricing model which approximates a binomial lattice model. In determining the expected term, the Company separate groups of employees that have historically exhibited similar behavior regarding option exercises and post-vesting cancellations. The option-pricing model requires the input of subjective assumptions, such as those included in the table below. The volatility rates are based principally on our historical stock prices and expectations of the future volatility of its Common Stock. The risk-free interest rate is based on the U.S. Treasury Yield curve in effect at the time of grant. The total expense to be recorded in future periods will depend on several variables, including the number of share-based awards and expected vesting. The following table summarizes warrants that we granted during the year ended December 31, 2017 and 2018: Grant Date Quantity Issued Expected Life (Years) Strike Price Volatility Dividend Yield Risk-Free Interest Rate Grant Date Fair Value Aggregate Fair Value 04/23/2018 1,000,000 10.0 $ 0.25 126.00 % 0 % 2.47 % $ 0.08 $ 80,000 11/14/2017 700,000 10.0 $ 0.25 116.47 % 0 % 2.33 % $ 0.11 79,222 10/09/2017 1,000,000 10.0 $ 0.25 115.00 % 0 % 2.47 % $ 0.16 150,000 The Company did not grant any warrants after 2018 and had total warrants issued and outstanding to third party consultants of 2,700,000 as of March 31, 2020.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 8—Subsequent Events The following significant events took place after the period covered by this report: Matters Relating to Our Relationship with Shanxi Taxus Pharmaceuticals Inc. and Affiliated Entities In April 2020, the Company entered into a Reaffirmation and Ratification Agreement with Shanxi Taxus Pharmaceuticals Co., Ltd. (“Shanxi”). Shanxi has previously paid a subscription of $600,000 to acquire shares of our Common Stock or shares of capital stock in our Angionetics Inc. subsidiary. In exchange for the cancellation of the $600,000 stock subscription agreement the Company entered into the two agreements described below and terminated all prior agreements with Shanxi and entered into a mutual release of claims. Generx Product In April 2020, Angionetics, Inc. entered into a Distribution and License Agreement with Shanxi, as amended by the First Amendment to Distribution and License Agreement dated April 14, 2020 (as amended, the “Shanxi License Agreement”), granting Shanxi certain license rights with respect to our Generx product candidate. The distribution and license rights commence only after the Company obtains U.S. FDA approval for marketing and sale of Generx in the United States. The license rights include (a) a non-exclusive right to manufacture Generx products in China, and (b) an exclusive right to market and sell Generx products in Singapore, Macau, Hong Kong, Taiwan, any other municipality other than mainland China where Chinese (Mandarin or Cantonese) is the common language, the Russian Federation and the Commonwealth of Independent States (i.e., Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan). The Shanxi License Agreement provides for a royalty ranging from 5% up to 10% based on the level of annual net sales of the Generx product sold by Shanxi in the licensed territory. Excellagen Product In April 2020, subsequent to the date of this report, the Company’s Activation Therapeutics, Inc. subsidiary entered into the Shanxi Assignment Agreement pursuant to which the Company transferred all of its license rights to manufacture, use, market and sell Excellagen in China to Shanxi. The Company also assigned to Shanxi a Chinese patent that the Company received on Excellagen. As a result, the Company no longer has an interest in Excellagen, other than the right to the royalty payments from Olaregen. Nostrum Financing On May 22, 2020, subsequent to the date of this report, the Company entered into a Preferred Stock Purchase Agreement (the “Agreement”) with Nostrum Pharmaceuticals, LLC, a Delaware limited liability company (“Nostrum”) pursuant to which the Company sold Nostrum 1,700,000 shares of newly designated Series B Preferred Stock, for a total cash consideration of $1.7 million. Series B Preferred Stock is convertible into shares of our common stock at an initial conversion ratio of $.0113 shares of Series B Preferred Stock for each share of common stock or 150,442,478 shares of the Company’s Common Stock. used the proceeds from the sale of the Series B Convertible Preferred Stock to fund working capital requirements in preparation for conducting a Phase 3 clinical trial in the U.S. for our Generx product candidate. We believe that Nostrum’s assets and experience in the formulation and commercialization of pharmaceutical products will facilitate the administration and completion of the Phase 3 clinical trial for Generx on a cost-effective basis. Nostrum is the parent of Nostrum Laboratories, Inc., a privately held pharmaceutical company engaged in the formulation and commercialization of specialty pharmaceutical products and controlled release, orally administered branded and generic drug products. Concurrently with the sale of the Series B Preferred Stock, Nostrum acquired 220 shares of the Company’s Series A Preferred Stock from Sabby Master Healthcare Ltd. and agreed to purchase the remaining 570 shares of Series A Convertible Preferred Stock that are outstanding and held by Sabby. As a result of the issuance of the Series B Convertible Preferred Stock, each share of our Series A Convertible Preferred Stock became convertible into 88,496 shares of our Common Stock. The Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock restricts Nostrum from converting any Series A Preferred Stock if Nostrum would beneficially own a number of shares of Common Stock in excess of 9.99% of the shares of Common Stock then issued and outstanding. As a result of its ownership of the Series B Convertible Preferred Stock, Nostrum is currently limited in its entirety from converting any shares of Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has no voting rights on general corporate matters, provided that the Series A Convertible Preferred Stock contain customary protective provisions. As of April 28, 2021, Sabby converted all of its remaining 570 shares of Series A Convertible Preferred Stock into 50,442,489 shares of Common and no further shares of the Series A Convertible Preferred Stock were purchased by Nostrum. As a result, Nostrum did not acquire any further shares of the Series A Convertible Preferred beyond their initial 220 share acquisition For the period May 2021 through July 2021, Nostrum provided an additional $292,000 in cash funding to support the operations of the Company to execute on our current business plan and seek alternative sources of non-dilutive capital to fund the Company’s research, development and commercialization activities for our lead product Generx [Ad5FGF-4]. The Company will issue an additional 292,000 of Series B Preferred Stock in exchange for the additional funding from Nostrum. Office Lease In July 2020, the Company entered into a twenty-nine-month lease for approximately 3,039 square feet of office space in San Diego, California commencing on August 1, 2020. The monthly base rent is $6,685 and increases by three percent (3%) on each anniversary of the Commencement Date. Retirement of Members of the Board of Directors & Bylaw Amendment to Change the Term Period On May 22, 2020, Andrew Leitch, John Wallace, Jiayue Zhang and Wei-Wei Zhang resigned as members of the Company’s Board of Directors. The resignations were required under the terms of the Series B Preferred Stock Purchase Agreement. On May 22, 2020, at the request of Nostrum, James Grainer and Kaushik K. Vyas were appointed to the Company’s Board of Directors and James L. Grainer was appointed to serve as Chairman of the Board. n May 22, 2020, the Board amended the Company’s bylaws to eliminate the classified Board. Directors will serve one-year terms until the next annual meeting of stockholders or until their successors are duly elected and qualified. Fuji Film Agreement In March 2021, the Company entered into an agreement with FUJIFILM Diosynth Biotechnologies (“FDB”) to manufacture the Generx [Ad5FGF-4] angiogenic gene therapy product candidate for Phase 3 clinical evaluation for the treatment of refractory angina due to late-stage coronary artery disease. Manufacturing operations will be conducted at FDB’s facilities in College Station, Texas where FDB will perform technology transfer and process development activities for Phase 3 clinical and commercial-scale GMP manufacturing of Generx.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, accounts receivable, inventories, accounts payable, and accrued liabilities approximate fair value due to the short-term maturities of these instruments.
Use of Estimates and Assumptions and Critical Accounting Estimates and Assumptions	Use of Estimates and assumptions and critical accounting estimates and assumptions. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Gene Biotherapeutics Inc., and its consolidated subsidiaries, Angionetics Inc., Activation Therapeutics, Inc. and LifeAgain Insurance Solutions, Inc. All significant inter-company transactions and balances have been eliminated in consolidation. The profit and losses of Angionetics are allocated among the controlling interest and the non-controlling interest in the same proportions as their ownership interests.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist of cash and cash equivalents. At times, our cash and cash equivalents may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. As of March 31, 2020, the Company had no cash and cash equivalent balances in excess of the federally insured limit of $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.
Property and Equipment, Net	Property and Equipment, net Property and equipment are stated at cost and include equipment, installation costs and materials less accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of the assets range from 3 to 5 years. Leasehold improvements are amortized over the lesser of the useful lives or the term of the respective lease. Expenditures for maintenance and repairs, which do not extend the useful life of the assets, are charged to expense as incurred. Gains or losses on disposal of property and equipment are reflected in general and administrative expenses in the statement of operations.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assts are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized no impairment losses during any of the periods presented in these financial statements.
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Revenue Recognition	Revenue Recognition The Company’s products have not reached commercialization, accordingly revenue from product sales have not been recognized. For arrangements that include sales-based royalties, the Company recognizes revenue based on an assessment of the probability of achievement. There is considerable judgement involved in determining whether it is probable that royalties will be collected. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement and if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. To date, the Company has not recognized revenue from product sales or for royalties.
Research and Development	Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for research and development employees.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income(loss) in the years in which those temporary differences are expected to be recovered or settled. Due to the Company’s history of losses, a full valuation allowance was recognized against the deferred tax assets as of December 31,2020. The Company expects that it will continue to experience operating losses. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the three-month period ended March 31, 2020, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes in unrecognized tax benefits within the next twelve months. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes our tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits. Under the provision of ASC 740-10, the Company recognizes the impact of a tax position in its financial statements if the position is more likely than not to be sustained upon examination based on the technical merits of the position. For the year period ended March 31, 2020, the Company had no material unrecognized tax benefits, and based on the information currently available, no significant changes in unrecognized tax benefits are expected in the next twelve months As of the tax year ending December 31,2019 the Company has net operating loss carryforwards for federal income tax purposes of approximately $91.4 million and net operating loss carryforwards for state income tax purposes of approximately $52.5 million. The net operating losses begin to expire in 2023 for federal income purposes and in 2028 for state income tax purposes. The federal net operating loss carryover includes $258,000 of net operating losses generated in 2018 and later. Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income. The Company also has R&D tax credits available for federal and state purposes of $1.8 million and $1.9 million, respectively. The federal R&D credits will begin to expire December 31, 2035. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those net operating losses are available. The Company considers projected future taxable income and tax planning strategies in making their assessment. At present, the Company does not have a sufficient history of income to conclude that it is more-likely-than-not that the Company will be able to realize all of our tax benefits in the near future and therefore the Company has established a valuation allowance for the full value of the deferred tax asset. In December 2017, the Tax Cuts and Jobs Act (the “2017 Act) was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 34 percent to 21 percent for tax years beginning after December 31, 2017. In 2017, the Company recorded provisional amounts for certain enactment-date effects of the act by applying the guidance in Staff Accounting Bulletin No. 118 (“SAB 118”). In 2018 and 2017, the Company recorded $0 net tax expense related to the enactment-date effects of the Act related to the remeasurement of deferred tax assets and liabilities. As of December 31, 2018, the Company completed its accounting for all of the enactment-date income tax effects of the Act and no adjustments were made to the provisional amounts recorded on December 31, 2017. As of December 31, 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they were expected to reverse in the future (which was generally 21%), by recording a provisional amount of $14.5 million, which was fully offset by valuation allowance. Upon further analysis of certain aspects of the Act and refinement of our calculations during the 12 months ended December 31, 2018, the Company determined that no adjustment was necessary to our provisional amount. Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC Section 382 and 383, the Company’s ability to use net operating loss and R&D tax credit carryforwards (“tax attribute carries forwards”) to offset future taxable income is limited if we experience a cumulative change in ownership of more than 50% within a three-year testing period. The Company had an ownership change on May 22, 2020 as result of the Nostrum investment. Accordingly for periods subsequent to May 22, 2020, the annual utilization of the net operating losses that are carried forward are expected to be limited. Further, the Company’s deferred tax assets associated with such tax attributes are expected to be significantly reduced upon realization of the ownership change within the meaning of IRC 382. The Company incurred an operating loss for the period ended March 31, 2020 and expects to have operating losses and federal and state tax losses for the full year December 31, 2020.
Common Stock Purchase Warrants	Common Stock Purchase Warrants The Company accounts for the issuance of common stock purchase warrants issued in connection with capital financing transactions. The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside of our control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
Earnings (loss) Per Common Share	Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss attributable to the controlling interest per common share for the three-month period ended March 31, 2020, because their effect would be anti-dilutive. As of March 31, 2020, there were potentially dilutive securities issued and outstanding which consisted of Series A Convertible Preferred Stock, that were convertible into 4,388,889 share of Common Stock, and there were stock options and warrants to acquire up to 14,811,333 shares of the Company’s Common Stock.
Stock-based Compensation	Stock-Based Compensation The Company recognizes the fair value of all share-based payment awards in the Statement of Operations over the requisite vesting period for each expected volatility, expected term, and risk-free interest rate. The Company estimated the fair value of an option award on the date of grant using the Black–Scholes option valuation model. The Black–Scholes option valuation model requires the development of assumptions that are input into the model. These assumptions are the expected stock volatility, the risk–free interest rate, the option’s expected life, the dividend yield on the underlying stock and the expected forfeiture rate. Expected volatility is calculated based on the historical volatility of our common stock over the expected option life and other appropriate factors. Risk–free interest rates are calculated based on continuously compounded risk–free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on its common stock and does not intend to pay dividends on its common stock in the foreseeable future. The expected forfeiture rate is estimated based on historical experience. Determining the appropriate fair value model and calculating the fair value of equity–based payment awards require the input of the subjective assumptions described above. The assumptions used in calculating the fair value of equity–based payment awards represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and the Company uses different assumptions, equity–based compensation could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If the actual forfeiture rate is materially different from the estimates, the equity–based compensation could be significantly different from what the Company has recorded in the current period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: March 31, December 31, 2020 2019 Computer and telecommunication equipment $ 12,902 $ 12,902 Office equipment 5,871 5,871 Office furniture and equipment 7,396 7,396 Leasehold improvements 177,436 177,436 203,605 203,605 Accumulated depreciation and amortization (201,386 ) (200,965 ) Property and equipment, net $ 2,219 $ 2,640

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued Liabilities consisted of the following: March 31, December 31, 2020 2019 Payroll and benefits $ 2,761,467 $ 2,657,717 Other 128,973 138,973 Total $ 2,890,440 $ 2,796,690

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Stock Option and Warrants Activity	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Balance outstanding, January 1, 2017 12,116,334 $ 0.62 7.67 Granted — — — Exercised — — — Cancelled (unvested) — — — Expired (vested) (5,001 ) 0.62 — Balance outstanding, December 31, 2017 12,111,333 0.62 6.67 Granted — — — Exercised — — — Cancelled (unvested) — — — Expired (vested) — — — Balance outstanding, December 31, 2018 12,111,333 $ 0.62 5.67 Granted — — — Exercised — — — Cancelled (unvested) — — — Expired (vested) — — — Balance outstanding, December 31, 2019 12,111,333 $ 0.62 4.67 Balance exercisable, December 31, 2019 12,111,333 $ 0.62 4.67 Balance exercisable, March 31, 2020 12,111,333 $ 0.62 4.42
Schedule of Granted Stock Options and Warrants	The following table summarizes warrants that we granted during the year ended December 31, 2017 and 2018: Grant Date Quantity Issued Expected Life (Years) Strike Price Volatility Dividend Yield Risk-Free Interest Rate Grant Date Fair Value Aggregate Fair Value 04/23/2018 1,000,000 10.0 $ 0.25 126.00 % 0 % 2.47 % $ 0.08 $ 80,000 11/14/2017 700,000 10.0 $ 0.25 116.47 % 0 % 2.33 % $ 0.11 79,222 10/09/2017 1,000,000 10.0 $ 0.25 115.00 % 0 % 2.47 % $ 0.16 150,000

Organization and Liquidity (Det

Organization and Liquidity (Details Narrative) - USD ($)	Apr. 10, 2020	Jun. 30, 2021	May 31, 2020	Jul. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Incorporation date						Dec. 31, 2003
Revenue
Cash and cash equivalents						2,926		$ 400
Working capital deficit						4,787,597
Accumulated deficit						(119,062,053)		(118,912,290)
Net cash used in operating activities						$ 93,857	$ 40,344
Debt forgiveness								$ 1,660,000
Subsequent Event [Member]
Debt forgiveness					$ 68,000
Subsequent Event [Member] | Series B Preferred Stock [Member]
Number of stock issued			1,700,000
Sale of stock cash consideration		$ 292,000	$ 1,700,000	$ 292,000
Subsequent Event [Member] | Maximum [Member] | Shanxi License Agreement [Member]
Revenue percentage	10.00%
Subsequent Event [Member] | Minimum [Member] | Shanxi License Agreement [Member]
Revenue percentage	5.00%
Subsequent Event [Member] | Excellagen [Member] | Olaregen Therapeutix, Inc [Member] | Maximum [Member]
Royalty income	$ 3,350,000
Subsequent Event [Member] | Excellagen [Member] | Shanxi Taxus Pharmaceuticals Co. Ltd. [Member]
Subscription payment	$ 600,000
Angionetics [Member]
Equity-based investment ownership percentage						85.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash, FDIC insured amount	$ 250,000
Income tax interest or penalties
Operating loss carryforwards, limitations on use			The net operating losses begin to expire in 2023 for federal income purposes and in 2028 for state income tax purposes.
Net operating losses	$ (152,883)	$ (242,978)
Tax credits carryforward description			Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income.
Income tax rate					21.00%
Deferred income tax provisional amount					$ 14,500,000
Stock Options and Warrants [Member] | Common Stock [Member]
Potentially dilutive securities	14,811,333
Convertible Series A Preferred Stock [Member]
Number of shares converted during period	4,388,889
Internal Revenue Code [Member]
Tax credits carryforward description	Pursuant to the Internal Revenue Code ("IRC") of 1986, as amended, specifically IRC Section 382 and 383, the Company's ability to use net operating loss and R&D tax credit carryforwards ("tax attribute carries forwards") to offset future taxable income is limited if we experience a cumulative change in ownership of more than 50% within a three-year testing period. The Company had an ownership change on May 22, 2020 as result of the Nostrum investment. Accordingly for periods subsequent to May 22, 2020, the annual utilization of the net operating losses that are carried forward are expected to be limited. Further, the Company's deferred tax assets associated with such tax attributes are expected to be significantly reduced upon realization of the ownership change within the meaning of IRC 382.
R&D Tax Credits [Member]
Tax credit carryforward, expire date			Dec. 31, 2035
Federal [Member]
Operating loss carryforwards			$ 91,400,000
Net operating losses				$ (258,000)
Federal [Member] | R&D Tax Credits [Member]
Tax credit carryforward amount			1,800,000
State [Member]
Operating loss carryforwards			52,500,000
State [Member] | R&D Tax Credits [Member]
Tax credit carryforward amount			$ 1,900,000
Minimum [Member]
Property and equipment, estimated useful life	3 years
Maximum [Member]
Property and equipment, estimated useful life	5 years

Property and Equipment (Details

Property and Equipment (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 421

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 203,605	$ 203,605
Accumulated depreciation and amortization	(201,386)	(200,965)
Property and equipment, net	2,219	2,640
Computer and Telecommunication Equipment [Member]
Property and equipment, gross	12,902	12,902
Office Equipment [Member]
Property and equipment, gross	5,871	5,871
Office Furniture and Equipment [Member]
Property and equipment, gross	7,396	7,396
Leasehold Improvements [Member]
Property and equipment, gross	$ 177,436	$ 177,436

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Payroll and benefits	$ 2,761,467	$ 2,657,717
Other	128,973	138,973
Total	$ 2,890,440	$ 2,796,689

Advances from Related Party-O_2

Advances from Related Party-Officer (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Advances from related party, officer		$ 690,050	$ 725,425
Repayments of officer's loan		$ 35,375
Subsequent Event [Member]
Repayments of officer's loan	$ 20,000
Repayments of loan, description	Effective in June, 2020, the Company is repaying the loan in equal monthly installments of $20,000.

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Jul. 08, 2020USD ($)ft²	Nov. 30, 2019USD ($)	Oct. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jun. 30, 2016
Operating lease agreement, term								38 months
Base monthly rent on operating lease					$ 3,500	$ 3,700	$ 3,800
Contingency payments, description				The Company has not reflected the contingent amounts payable of $397,449 in the Consolidated Balance Sheet as the payable is contingent on FDA approval and commercialization of the product.
Former Employees [Member]
Contingency payments, description				In January 2020, all affected current and former employees agreed to defer their compensation, less applicable tax withholdings, upon the earliest to occur of (a) the FDA's approval of Generx for marketing and sale in the U.S.; (b) the EMA approval of Generx for marketing and sale in the European Union and the United Kingdom; (c) the sale of Generx to an independent third party for an aggregate value equal to or greater than $35,000,000; (d) our entry into a strategic partnership that would facilitate a capital contribution equal to or greater than $35,000,000 for the purpose of supporting the clinical and commercial development of Generx; (e) our successful completion of a public or private equity offering for the issuance of its common stock equal to $35,000,000; or (f) at such other time, as our board of directors determines that we have the financial ability to make such payments without jeopardizing our ability to operate as a going concern.
Unpaid deferred compensation, amount				$ 2,926,717
U.S. Food and Drug Administration [Member]
Contingency accrual, payments					$ 172,449
Contingency payments, description					The total liabilities payable by the Company in the event of FDA approval is $172,449 and an additional amount totaling $225,000 is payable when commercial sales cumulatively reach $100 million for Generx. Since the Company does not know if FDA approval will be received for the Generx product, it is not determinable if and when this payment will be made by the Company. Accordingly, these amounts have been reported as a contingent liability and have not been included in accounts payable and accrued liabilities.
UC License Agreements [Member]
Contingency accrual, payments			$ 100,000
Unpaid fees, outstanding			1,006,709
Litigation settlement, amount			172,449
Cash payments, quarterly			8,333
Additional lumpsum payment, payable			$ 72,449
Technology License Agreements [Member]
Litigation settlement, amount		$ 400,000
Litigation settlement payable, description		(1) $75,000 in six quarterly payments of $12,500 commencing June 15, 2020, with additional contingent payments due as follows (2) $100,000 payable upon FDA approval to market and sell Generx; and (3) an additional amount totaling $225,000 when commercial US sales cumulatively reach $100 million for Generx.
Subsequent Event [Member]
Base monthly rent on operating lease	$ 6,685
Area of land | ft²	3,039
Operating lease, description	The Company entered into a twenty-nine-month lease for approximately 3,039 square feet of office space in San Diego, California commencing on August 1, 2020.
Operating lease rent, annual increase percentage	3.00%
Final Two Months of Agreement [Member]
Base monthly rent on operating lease				3,900
Monthly base rent, total				$ 139,800

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)

Apr. 28, 2021

May 22, 2020

May 21, 2020

Apr. 30, 2018

Nov. 30, 2017

Oct. 31, 2017

Apr. 04, 2015

May 31, 2020

Jul. 31, 2015

Apr. 30, 2013

Mar. 31, 2020

Jun. 30, 2018

Dec. 31, 2017

Sep. 30, 2020

Dec. 31, 2019

Dec. 31, 2005

Number of options and warrants, outstanding

14,811,333

Number of options and warrants, exercisable

14,811,333

Weighted average exercise price, outstanding

$ 0.62

Weighted average exercise price, exercisable

$ 0.62

Weighted average remaining contractual life (in years), outstanding

4 years 3 months 29 days

Weighted average remaining contractual life (in years), exercisable

4 years 3 months 29 days

Intrinsic value of outstanding options

$ 0

Intrinsic value of outstanding warrants

0

Intrinsic value of exercisable options

0

Intrinsic value of exercisable warrants

$ 0

Subsequent Event [Member] | Equity Incentive Plan [Member]

Number of stock options, warrant issued

0

Subsequent Event [Member] | Outside of Plan To Employees and Consultants [Member]

Number of stock options, warrant issued

0

Subsequent Event [Member] | Director [Member]

Serving term

1 year

Common Stock [Member] | Equity Incentive Plan [Member]

Number of common shares reserved for issuance

283,058

Warrant [Member] | Consultant [Member]

Warrants issued during period

700,000

Warrants exercisable, description

The warrants are exercisable at any time from November 14, 2017 (the grant date) for a period up to 10 years at an exercise price of $0.25 per share.

Warrants exercise price, per share

$ 0.25

Warrants fair value, per share

$ 0.11

Consulting costs

$ 79,222

Warrant [Member] | Third Party Consultants [Member]

Warrants issued during period

2,700,000

Warrants outstanding during period

$ 2,700,000

Convertible Series A Preferred Stock [Member]

Number of shares converted during period

4,388,889

Series B Preferred Stock [Member] | Subsequent Event [Member]

Number of common shares sold during period

1,700,000

Series B Convertible Preferred Stock [Member] | Subsequent Event [Member]

Shares conversion price, per share

$ 0.0113

Debt conversion of convertible shares

88.5

Conversion description

If the Company sells shares of Common Stock or Common Stock equivalents at a price less than the current conversion price, the conversion price of the Series B Convertible Preferred Stock will be reduced to equal eighty percent (80%) of the price at which such Common Stock or Common Stock equivalents are sold.

Description liquidation

Upon any liquidation, dissolution or winding up of our company, after payment or provision for payment of our debts and other liabilities and before any distribution or payment is made to the holders of our common stock or any junior securities, the holders of our Series B Convertible Preferred Stock will first be entitled to be paid an amount equal to $1.00 per share plus any other fees, liquidated damages or dividends then owing, before our remaining assets will be distributed among the holders of the other classes or series of shares of our capital stock in accordance with our Certificate of Incorporation.

Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]

Debt conversion of convertible shares

88,496

Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Subsequent Event [Member]

Debt conversion of convertible shares

50,442,489

50,442,489

Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Preferred Stock [Member] | Subsequent Event [Member]

Number of shares issued during period

1,700,000

Shares conversion price, per share

$ 0.0113

Shares issued value

$ 1,700,000

Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Preferred Stock [Member] | Common Stock [Member] | Subsequent Event [Member]

Debt conversion of convertible shares

150,442,478

Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member] | Subsequent Event [Member]

Number of shares issued during period

1,700,000

Shares issued value

$ 1,700,000

Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Convertible Preferred Stock [Member] | Common Stock [Member] | Subsequent Event [Member]

Debt conversion of convertible shares

50,442,489

88,496

150,442,478

Shenzhen Qianhai Taxus Capital Management Co., Ltd. [Member]

Number of common shares sold during period

600,000

Proceeds from common stock issued

$ 600,000

Equity shares ownership percentage

24.00%

Equity shares voting percentage, description

The Nostrum Series B Preferred stock investment and excluding Nostrum's Series A Preferred Stock investment and pending Series B Preferred issuances Shenzhen Qianhai Taxus and Nostrum own 1.6% and 70% of the voting common stock respectively as of August 28,2021.

Equity, shares ownership percentage

24.00%

Shenzhen Qianhai Taxus Capital Management Co., Ltd. [Member] | Angionetics [Member]

Proceeds from common stock issued

3,000,000

Shenzhen Qianhai Taxus Capital Management Co., Ltd. [Member] | Angionetics [Member] | Tranches [Member]

Proceeds from common stock issued

$ 3,000,000

Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member]

Equity shares ownership percentage, description

Sabby is limited to hold no more than 10% of Gene Biotherapeutics' issued and outstanding common stock at any time.

Preferred stock, outstanding

790

790

Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member] | Common Stock [Member]

Number of shares converted during period

3,918,667

Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member] | Common Stock [Member] | Before Conversion Price Change [Member]

Number of shares converted during period

2,092,350

Sabby Healthcare Volatility Master Fund, Ltd. [Member] | Exchange and Redemption Agreement [Member] | Convertible Series A Preferred Stock [Member]

Number of shares issued during period

4,012

Proceeds from issuance of preferred stock

$ 4,000,000

Shares conversion price, per share

$ 0.30

$ 0.6437

Preferred stock, outstanding

1,176

Exchange and redemption agreement, description

The Agreement grants Gene Biotherapeutics (1) a right to redeem any or all of the outstanding Preferred Stock for its stated value (approximately $1,000 per share) at any time during a 120-day period after the date of the Agreement, and (2) increases the limitation on certain indebtedness contained in the Certificate of Designation for the Preferred Stock to allow Gene Biotherapeutics to borrow up to $250,000.

Sabby Master Healthcare Ltd [Member] | Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]

Number of shares issued during period

570

570

220

Common stock issued and outstanding percentage

999.00%

Sabby Master Healthcare Ltd [Member] | Nostrum Pharmaceuticals, LLC [Member] | Preferred Stock Purchase Agreement [Member] | Series B Preferred Stock [Member] | Subsequent Event [Member]

Number of shares issued during period

220

570

Landmark Pegasus, Inc. [Member]

Consulting costs

$ 150,000

Landmark Pegasus, Inc. [Member] | Warrant [Member]

Warrants issued during period

1,000,000

1,000,000

Warrants exercisable, description

The Common Stock warrants are exercisable at any time from April 23, 2018 (initial exercise date) and on or prior to the close of business on the 10-year anniversary from the initial exercise date, April 22, 2028,

The warrants are exercisable at any time from October 9, 2017 (initial exercise date) and on or prior to the close of business on the 10-year anniversary from the initial exercise date, October 8, 2027,

Warrants exercise price, per share

$ 0.25

$ 0.25

Warrants fair value, per share

$ 0.08

$ 0.15

Consulting costs

$ 80,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Option and Warrants Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of Options or Warrants, Balance outstanding, Ending	14,811,333
Number of Options or Warrants, Exercisable, Ending	14,811,333
Weighted Average Exercise Price, Balance outstanding, Ending	$ 0.62
Weighted Average Exercise Price, Exercisable, Ending	$ 0.62
Weighted Average Remaining Contractual Life (in years), Ending	4 years 3 months 29 days
Weighted Average Remaining Contractual Life (in years), Exercisable, Ending Balance	4 years 3 months 29 days
Directors And Employees [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of Options or Warrants, Balance outstanding, Beginning	12,111,333	12,111,333	12,111,333	12,111,333	12,116,334
Number of Options or Warrants, Granted
Number of Options or Warrants, Exercised
Number of Options or Warrants, Cancelled (unvested)
Number of Options or Warrants, Expired (vested)					(5,001)
Number of Options or Warrants, Balance outstanding, Ending			12,111,333	12,111,333	12,111,333
Number of Options or Warrants, Exercisable, Ending		12,111,333	12,111,333
Weighted Average Exercise Price, Balance outstanding, Beginning	$ 0.62	$ 0.62	$ 0.62	$ 0.62	$ 0.62
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled (unvested)
Weighted Average Exercise Price, Expired (vested)					0.62
Weighted Average Exercise Price, Balance outstanding, Ending			0.62	$ 0.62	$ 0.62
Weighted Average Exercise Price, Exercisable, Ending		$ 0.62	$ 0.62
Weighted Average Remaining Contractual Life (in years), Beginning		4 years 8 months 2 days	5 years 8 months 2 days	6 years 8 months 2 days	7 years 8 months 2 days
Weighted Average Remaining Contractual Life (in years), Ending			4 years 8 months 2 days	5 years 8 months 2 days	6 years 8 months 2 days
Weighted Average Remaining Contractual Life (in years), Exercisable, Ending Balance		4 years 5 months 1 day	4 years 8 months 2 days

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Granted Stock Options and Warrants (Details) - Stock Option And Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Grant Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	Apr. 23, 2018	Apr. 23, 2018
Quantity Issued	1,000,000	1,000,000
Expected Life (Years)	10 years	10 years
Strike Price	$ 0.25	$ 0.25
Volatility	126.00%	126.00%
Dividend Yield	0.00%	0.00%
Risk-Free Interest Rate	2.47%	2.47%
Grant Date Fair Value Per warrant	$ 0.08	$ 0.08
Aggregate Fair Value	$ 80,000	$ 80,000
Grant Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	Nov. 14, 2017	Nov. 14, 2017
Quantity Issued	700,000	700,000
Expected Life (Years)	10 years	10 years
Strike Price	$ 0.25	$ 0.25
Volatility	116.47%	116.47%
Dividend Yield	0.00%	0.00%
Risk-Free Interest Rate	2.33%	2.33%
Grant Date Fair Value Per warrant	$ 0.11	$ 0.11
Aggregate Fair Value	$ 79,222	$ 79,222
Grant Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	Oct. 9, 2017	Oct. 9, 2017
Quantity Issued	1,000,000	1,000,000
Expected Life (Years)	10 years	10 years
Strike Price	$ 0.25	$ 0.25
Volatility	115.00%	115.00%
Dividend Yield	0.00%	0.00%
Risk-Free Interest Rate	2.47%	2.47%
Grant Date Fair Value Per warrant	$ 0.16	$ 0.16
Aggregate Fair Value	$ 150,000	$ 150,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Apr. 28, 2021shares	May 22, 2020USD ($)$ / sharesshares	May 21, 2020$ / sharesshares	Apr. 14, 2020	Jun. 30, 2021USD ($)	Jul. 31, 2020USD ($)ft²	May 31, 2020USD ($)shares	Apr. 30, 2020USD ($)	Jul. 31, 2021USD ($)
Series B Preferred Stock [Member]
Sale of stock cash consideration | $					$ 292,000		$ 1,700,000		$ 292,000
Series B Convertible Preferred Stock [Member]
Debt conversion price per share | $ / shares			$ 0.0113
Debt conversion of convertible shares			88.5
Conversion description			If the Company sells shares of Common Stock or Common Stock equivalents at a price less than the current conversion price, the conversion price of the Series B Convertible Preferred Stock will be reduced to equal eighty percent (80%) of the price at which such Common Stock or Common Stock equivalents are sold.
Description liquidation			Upon any liquidation, dissolution or winding up of our company, after payment or provision for payment of our debts and other liabilities and before any distribution or payment is made to the holders of our common stock or any junior securities, the holders of our Series B Convertible Preferred Stock will first be entitled to be paid an amount equal to $1.00 per share plus any other fees, liquidated damages or dividends then owing, before our remaining assets will be distributed among the holders of the other classes or series of shares of our capital stock in accordance with our Certificate of Incorporation.
Nostrum Pharmaceuticals, LLC [Member]
Sale of stock cash consideration | $									$ 292,000
Reaffirmation and Ratification Agreement [Member] | Shanxi Taxus Pharmaceuticals Co. Ltd. [Member]
Subscription payment to acquire shares | $								$ 600,000
Payment to the purchase of license rights | $								$ 600,000
Shanxi License Agreement [Member] | Angionetics [Member]
Distribution and license rights description				The distribution and license rights commence only after the Company obtains U.S. FDA approval for marketing and sale of Generx in the United States. The license rights include (a) a non-exclusive right to manufacture Generx products in China, and (b) an exclusive right to market and sell Generx products in Singapore, Macau, Hong Kong, Taiwan, any other municipality other than mainland China where Chinese (Mandarin or Cantonese) is the common language, the Russian Federation and the Commonwealth of Independent States (i.e., Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan).
Shanxi License Agreement [Member] | Angionetics [Member] | Minimum [Member]
Royalty range				5.00%
Shanxi License Agreement [Member] | Angionetics [Member] | Maximum [Member]
Royalty range				10.00%
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series B Preferred Stock [Member]
Debt conversion price per share | $ / shares		$ 0.0113
Shares issued		1,700,000
Shares issued value | $		$ 1,700,000
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series B Preferred Stock [Member] | Sabby Master Healthcare Ltd [Member]
Shares issued	220						570
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series B Preferred Stock [Member] | Common Stock [Member]
Debt conversion of convertible shares		150,442,478
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series A Preferred Stock [Member] | Sabby Master Healthcare Ltd [Member]
Shares issued	220	220
Common stock issued and outstanding percentage		9.99%
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series A Convertible Preferred Stock [Member]
Debt conversion of convertible shares							88,496
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series A Convertible Preferred Stock [Member] | Sabby Master Healthcare Ltd [Member]
Shares issued	570	570					220
Common stock issued and outstanding percentage							999.00%
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series A Convertible Preferred Stock [Member] | Common Stock [Member]
Debt conversion of convertible shares	50,442,489						50,442,489
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series B Convertible Preferred Stock [Member]
Shares issued							1,700,000
Shares issued value | $							$ 1,700,000
Preferred Stock Purchase Agreement [Member] | Nostrum Pharmaceuticals, LLC [Member] | Series B Convertible Preferred Stock [Member] | Common Stock [Member]
Debt conversion of convertible shares	50,442,489	88,496					150,442,478
Office Lease [Member]
Office space | ft²						3,039
Monthly base rent | $						$ 6,685
Percent increases in base rent						3.00%